Partial
Partially Aligned
Patient Risk:
Low
Summary
Most non-safety statements about CRESTOR vs rosuvastatin and tablet strengths are consistent with label excerpts provided (Sections 3 and general dosing range/administration). However, multiple claims about switching equivalence, practical substitutability “without changing results,” and “usually do not change” cholesterol-lowering effect are not supported by the provided prescribing information. Some safety-related suggestion wording (discussion with clinician for kidney/liver conditions) is not grounded in the excerpted label text as a specific recommendation.
Category Scores
Accurate Statements
Crestor is sold in multiple dose strengths including 5 mg, 10 mg, 20 mg, and 40 mg.
Supported by Section 3 (DOSAGE FORMS AND STRENGTHS) listing tablets: 5 mg, 10 mg, 20 mg, 40 mg.
Rosuvastatin and Crestor are the same medication when the product contains rosuvastatin at the same strength.
Consistent with label excerpt that CRESTOR tablets are rosuvastatin (Section 3) and that CRESTOR is rosuvastatin (implied by labeling context in Sections 2/3/12).
“Crestor 20 mg” and “rosuvastatin 20 mg” generally correspond to the same dose of the active drug.
Supported by Section 3 describing CRESTOR tablets by rosuvastatin strengths (e.g., 20 mg).
Unsupported Statements
Switching from Crestor to rosuvastatin is often possible without changing results because they use the same active ingredient.
The provided prescribing information excerpts do not discuss brand-to-generic switching, therapeutic equivalence, or maintaining results after switching.
Differences in non-medicinal components such as fillers, dyes, and tablet coatings usually do not change the drug’s cholesterol-lowering effect because the active ingredient is the same.
The provided prescribing information excerpts do not discuss excipients or how excipient differences affect lipid-lowering efficacy.
Generic rosuvastatin products come in the same dose strengths as Crestor.
The provided label excerpts describe CRESTOR strengths (Section 3) but do not state the available strengths of generic rosuvastatin products.
Switching is worth discussing with a clinician or pharmacist, especially if you’ve had side effects, are taking other cholesterol medicines, or have kidney or liver conditions.
The excerpts identify risks (e.g., myopathy risk factors including renal impairment; contraindication in acute liver failure/decompensated cirrhosis; and dose considerations/risks with certain drugs) but do not provide an instruction specifically about discussing switching with a clinician/pharmacist in these scenarios.
Contradictions
Low
AI Statement
The key is to match the dose (mg) of rosuvastatin.
Label Reference
Not directly contradicted by the provided excerpts.
Important Omissions
When discussing safety around dosing changes or switching, the provided label excerpt specifically includes monitoring and risk-factor guidance (e.g., myopathy/rhabdomyolysis risk factors; renal impairment dosing limits; hepatic contraindications). The AI did not cite or accurately map these label-based safety considerations to the switching context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims are largely administrative/pharmacologic equivalence statements. The primary potential risk stems from unsupported over-assurance about switching without changing results and generic availability; however, no direct dosing harm or direct contraindication breach is claimed in the provided response.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several statements about switching equivalence and excipient-driven effects are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit claims to what is supported: CRESTOR contains rosuvastatin and is available in 5/10/20/40 mg strengths (Section 3) and CRESTOR dosage range/administration basics (Section 2). Avoid asserting that switching to generic rosuvastatin will not change results or that excipient differences usually do not affect efficacy, unless the label excerpts explicitly address this.